Last reviewed · How we verify
NCT01926743
Identification of Complete Lymph Node Removal by Application of Near Infrared Fluorescence Imaging in Laparoscopic and Robotic Gastrectomy
NA trial testing Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy in Gastric Cancer in 40 participants. Completed in 31 January 2014.
31 January 2014
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 August 2013 |
| Primary completion | 31 January 2014 |
| Estimated completion | 31 January 2014 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Yonsei University
Who can join
Adults 20 to 80, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymph node dissection in gastric cancer surgery is a very important factor not only for exact acquisition of stage but also proper treatment. Realistically, it is impossible to identify complete removal of lymph node in dissected nodal station by naked eye. The investigators can assess the route of lymphatic drainage and identify residual lymph nodes in dissected area. In the field of gastric cancer treatment, ICG and near infra-red fluorescence imaging was used only detection of sentinel lymph nodes. However, this novel concept can help to understand lymphatic drainage and make surgeons to perform D1+ or D2 lymph node dissection completely.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Fluorescent Lymphography-Guided Lymphadenectomy During Robotic Radical Gastrectomy for Gastric Cancer.
Kwon IG, Son T, Kim HI, Hyung WJ. · · 2019 · cited 123× · PMID 30427990 · DOI 10.1001/jamasurg.2018.4267 -
Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.
Olson MT, Ly QP, Mohs AM. · · 2019 · cited 48× · PMID 29942988 · DOI 10.1007/s11307-018-1239-2 -
A pilot study of lymph node mapping with indocyanine green in robotic gastrectomy for gastric cancer.
Lan YT, Huang KH, Chen PH, Liu CA, et al · · 2017 · cited 45× · PMID 28856007 · DOI 10.1177/2050312117727444 -
Sentinel node navigation surgery for gastric cancer: Overview and perspective.
Yashiro M, Matsuoka T. · · 2015 · cited 21× · PMID 25625004 · DOI 10.4240/wjgs.v7.i1.1 -
Robotic surgery for gastric tumor: current status and new approaches.
Lim SH, Lee HM, Son T, Hyung WJ, et al · · 2016 · cited 8× · PMID 28138595 · DOI 10.21037/tgh.2016.03.21 -
Potential Probes for Targeted Intraoperative Fluorescence Imaging in Gastric Cancer.
Martinelli S, Fortuna L, Coratti F, Passagnoli F, et al · · 2024 · cited 4× · PMID 39766041 · DOI 10.3390/cancers16244141
Verify or expand the search:
- PubMed search for NCT01926743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01926743 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 6 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01926743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing